Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Remacemide: current status and clinical applications.

S C Schachter1, D Tarsy

  • 1Departments of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, K-478, Boston, MA 02215, USA. sschacht@caregroup.harvard.edu

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition.

Epilepsy research·2015
Same author

Mobility, mood and site of care impact health related quality of life in Parkinson's disease.

Parkinsonism & related disorders·2013
Same author

The "floating door sign" in Parkinson's disease.

Parkinsonism & related disorders·2013
Same author

Laserlight cues for gait freezing in Parkinson's disease: an open-label study.

Parkinsonism & related disorders·2010
Same author

Novel THAP1 sequence variants in primary dystonia.

Neurology·2010
Same author

Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.

Neuroscience·2007

Remacemide (RMC) is a novel NMDA receptor antagonist effective in treating epilepsy and Parkinson's disease without severe side effects. It shows promise for conditions involving glutamate-mediated neurotoxicity.

Area of Science:

  • Neuropharmacology
  • Neurology

Background:

  • N-methyl-D-aspartate (NMDA) receptor antagonists are crucial for treating neurological disorders.
  • Existing NMDA antagonists often present significant behavioral and neuropathological side effects.

Purpose of the Study:

  • To evaluate Remacemide (RMC), a novel NMDA receptor antagonist, for its efficacy and safety profile.
  • To explore RMC's potential therapeutic applications in neurological conditions.

Main Methods:

  • Preclinical studies in animal models of epilepsy, parkinsonism, and cerebral ischemia.
  • Clinical trials assessing RMC's efficacy in epilepsy and Parkinson's disease.
  • Pharmacokinetic and drug interaction studies, including metabolism via cytochrome P450 3A4.

Main Results:

Related Experiment Videos

  • RMC demonstrates efficacy in animal models and human studies for epilepsy and Parkinson's disease.
  • RMC exhibits a favorable safety profile, lacking teratogenic and genotoxic effects.
  • RMC interacts with neuronal sodium channels and has linear pharmacokinetics with moderate protein binding.

Conclusions:

  • Remacemide (RMC) is a promising therapeutic agent for neurological conditions linked to glutamate-mediated neurotoxicity.
  • RMC offers a potentially safer alternative to existing NMDA receptor antagonists.
  • Further research supports RMC's application in acute and chronic neurological disorders.